Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders

Autores
Martín Giménez, Virna Margarita; García Menéndez, Sebastián Marcelo Manuel; Sanz, Raul Lelio; Schiavone, Máximo; Ferder, Leon Fernando; Inserra, Pablo Ignacio Felipe; Manucha, Walter Ariel Fernando
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Hypertension disrupts cerebral blood flow, leading to endothelial dysfunction, breakdown of the blood-brain barrier, and infiltration of inflammatory cells. This cascade triggers the activation of glial cells, increases oxidative stress, and causes the release of pro-inflammatory cytokines, creating a neurotoxic environment. In this context, we explore the intricate connection between hypertension, neuroinflammation, and neurodegeneration, as well as how hypertension interacts with other metabolic disorders, such as obesity and diabetes, which further worsen neuroinflammation. Additionally, we discuss the role of the renin-angiotensin-aldosterone system (RAAS), the impact of the microbiome, and the potential contribution of chronic infections in exacerbating neuroinflammation.It is important to emphasize nanotechnology´s potential to transform therapeutic approaches. Nanoparticle-based drug delivery systems can enhance the bioavailability and selectivity of antihypertensive drugs, antioxidants, and neuroprotective compounds, enabling targeted delivery across the blood-brain barrier. By combining effective blood pressure management with nanotechnology-enabled therapies that modulate inflammation, oxidative stress, and protein aggregation, we can explore new avenues for preventing and treating neurodegenerative conditions associated with hypertension and metabolic disorders.Ultimately, hypertension significantly contributes to neuroinflammation and neurodegeneration by promoting inflammation, oxidative stress, and neuronal death, primarily through impaired cerebral blood flow and disruption of the blood-brain barrier. The interaction of hypertension with metabolic disorders exacerbates these effects. However, advancements in our understanding and new technologies reveal promising nanopharmacological approaches allowing targeted drug delivery to the brain, thereby improving treatment outcomes, enhancing adherence, and reducing side effects.
Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina
Fil: García Menéndez, Sebastián Marcelo Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Sanz, Raul Lelio. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina
Fil: Schiavone, Máximo. Universidad Austral; Argentina
Fil: Ferder, Leon Fernando. Universidad Maimónides; Argentina
Fil: Inserra, Pablo Ignacio Felipe. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Maimónides; Argentina
Fil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina
Materia
NANOPHARMACOLOGY
HYPERTENSION
NEUROINFLAMMATION
METABOLIC DISORDERS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/290988
Acceder
id CONICETDig_b27fdf0ba2563a8f0eb659a9710fa854
oai_identifier_str oai:ri.conicet.gov.ar:11336/290988
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disordersMartín Giménez, Virna MargaritaGarcía Menéndez, Sebastián Marcelo ManuelSanz, Raul LelioSchiavone, MáximoFerder, Leon FernandoInserra, Pablo Ignacio FelipeManucha, Walter Ariel FernandoNANOPHARMACOLOGYHYPERTENSIONNEUROINFLAMMATIONMETABOLIC DISORDERShttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Hypertension disrupts cerebral blood flow, leading to endothelial dysfunction, breakdown of the blood-brain barrier, and infiltration of inflammatory cells. This cascade triggers the activation of glial cells, increases oxidative stress, and causes the release of pro-inflammatory cytokines, creating a neurotoxic environment. In this context, we explore the intricate connection between hypertension, neuroinflammation, and neurodegeneration, as well as how hypertension interacts with other metabolic disorders, such as obesity and diabetes, which further worsen neuroinflammation. Additionally, we discuss the role of the renin-angiotensin-aldosterone system (RAAS), the impact of the microbiome, and the potential contribution of chronic infections in exacerbating neuroinflammation.It is important to emphasize nanotechnology´s potential to transform therapeutic approaches. Nanoparticle-based drug delivery systems can enhance the bioavailability and selectivity of antihypertensive drugs, antioxidants, and neuroprotective compounds, enabling targeted delivery across the blood-brain barrier. By combining effective blood pressure management with nanotechnology-enabled therapies that modulate inflammation, oxidative stress, and protein aggregation, we can explore new avenues for preventing and treating neurodegenerative conditions associated with hypertension and metabolic disorders.Ultimately, hypertension significantly contributes to neuroinflammation and neurodegeneration by promoting inflammation, oxidative stress, and neuronal death, primarily through impaired cerebral blood flow and disruption of the blood-brain barrier. The interaction of hypertension with metabolic disorders exacerbates these effects. However, advancements in our understanding and new technologies reveal promising nanopharmacological approaches allowing targeted drug delivery to the brain, thereby improving treatment outcomes, enhancing adherence, and reducing side effects.Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; ArgentinaFil: García Menéndez, Sebastián Marcelo Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Sanz, Raul Lelio. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; ArgentinaFil: Schiavone, Máximo. Universidad Austral; ArgentinaFil: Ferder, Leon Fernando. Universidad Maimónides; ArgentinaFil: Inserra, Pablo Ignacio Felipe. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Maimónides; ArgentinaFil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; ArgentinaBaishideng Publishing Group2025-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/290988Martín Giménez, Virna Margarita; García Menéndez, Sebastián Marcelo Manuel; Sanz, Raul Lelio; Schiavone, Máximo; Ferder, Leon Fernando; et al.; Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders; Baishideng Publishing Group; World Journal of Experimental Medicine; 15; 3; 9-2025; 1-92220-315XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/2220-315X/full/v15/i3/106743.htminfo:eu-repo/semantics/altIdentifier/doi/10.5493/wjem.v15.i3.106743info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T14:57:47Zoai:ri.conicet.gov.ar:11336/290988instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 14:57:47.733CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
title Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
spellingShingle Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
Martín Giménez, Virna Margarita
NANOPHARMACOLOGY
HYPERTENSION
NEUROINFLAMMATION
METABOLIC DISORDERS
title_short Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
title_full Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
title_fullStr Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
title_full_unstemmed Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
title_sort Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
dc.creator.none.fl_str_mv Martín Giménez, Virna Margarita
García Menéndez, Sebastián Marcelo Manuel
Sanz, Raul Lelio
Schiavone, Máximo
Ferder, Leon Fernando
Inserra, Pablo Ignacio Felipe
Manucha, Walter Ariel Fernando
author Martín Giménez, Virna Margarita
author_facet Martín Giménez, Virna Margarita
García Menéndez, Sebastián Marcelo Manuel
Sanz, Raul Lelio
Schiavone, Máximo
Ferder, Leon Fernando
Inserra, Pablo Ignacio Felipe
Manucha, Walter Ariel Fernando
author_role author
author2 García Menéndez, Sebastián Marcelo Manuel
Sanz, Raul Lelio
Schiavone, Máximo
Ferder, Leon Fernando
Inserra, Pablo Ignacio Felipe
Manucha, Walter Ariel Fernando
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv NANOPHARMACOLOGY
HYPERTENSION
NEUROINFLAMMATION
METABOLIC DISORDERS
topic NANOPHARMACOLOGY
HYPERTENSION
NEUROINFLAMMATION
METABOLIC DISORDERS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Hypertension disrupts cerebral blood flow, leading to endothelial dysfunction, breakdown of the blood-brain barrier, and infiltration of inflammatory cells. This cascade triggers the activation of glial cells, increases oxidative stress, and causes the release of pro-inflammatory cytokines, creating a neurotoxic environment. In this context, we explore the intricate connection between hypertension, neuroinflammation, and neurodegeneration, as well as how hypertension interacts with other metabolic disorders, such as obesity and diabetes, which further worsen neuroinflammation. Additionally, we discuss the role of the renin-angiotensin-aldosterone system (RAAS), the impact of the microbiome, and the potential contribution of chronic infections in exacerbating neuroinflammation.It is important to emphasize nanotechnology´s potential to transform therapeutic approaches. Nanoparticle-based drug delivery systems can enhance the bioavailability and selectivity of antihypertensive drugs, antioxidants, and neuroprotective compounds, enabling targeted delivery across the blood-brain barrier. By combining effective blood pressure management with nanotechnology-enabled therapies that modulate inflammation, oxidative stress, and protein aggregation, we can explore new avenues for preventing and treating neurodegenerative conditions associated with hypertension and metabolic disorders.Ultimately, hypertension significantly contributes to neuroinflammation and neurodegeneration by promoting inflammation, oxidative stress, and neuronal death, primarily through impaired cerebral blood flow and disruption of the blood-brain barrier. The interaction of hypertension with metabolic disorders exacerbates these effects. However, advancements in our understanding and new technologies reveal promising nanopharmacological approaches allowing targeted drug delivery to the brain, thereby improving treatment outcomes, enhancing adherence, and reducing side effects.
Fil: Martín Giménez, Virna Margarita. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Catolica de Cuyo - Sede San Juan. Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas. Instituto de Investigación en Ciencias Químicas; Argentina
Fil: García Menéndez, Sebastián Marcelo Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Sanz, Raul Lelio. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina
Fil: Schiavone, Máximo. Universidad Austral; Argentina
Fil: Ferder, Leon Fernando. Universidad Maimónides; Argentina
Fil: Inserra, Pablo Ignacio Felipe. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Maimónides; Argentina
Fil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina
description Hypertension disrupts cerebral blood flow, leading to endothelial dysfunction, breakdown of the blood-brain barrier, and infiltration of inflammatory cells. This cascade triggers the activation of glial cells, increases oxidative stress, and causes the release of pro-inflammatory cytokines, creating a neurotoxic environment. In this context, we explore the intricate connection between hypertension, neuroinflammation, and neurodegeneration, as well as how hypertension interacts with other metabolic disorders, such as obesity and diabetes, which further worsen neuroinflammation. Additionally, we discuss the role of the renin-angiotensin-aldosterone system (RAAS), the impact of the microbiome, and the potential contribution of chronic infections in exacerbating neuroinflammation.It is important to emphasize nanotechnology´s potential to transform therapeutic approaches. Nanoparticle-based drug delivery systems can enhance the bioavailability and selectivity of antihypertensive drugs, antioxidants, and neuroprotective compounds, enabling targeted delivery across the blood-brain barrier. By combining effective blood pressure management with nanotechnology-enabled therapies that modulate inflammation, oxidative stress, and protein aggregation, we can explore new avenues for preventing and treating neurodegenerative conditions associated with hypertension and metabolic disorders.Ultimately, hypertension significantly contributes to neuroinflammation and neurodegeneration by promoting inflammation, oxidative stress, and neuronal death, primarily through impaired cerebral blood flow and disruption of the blood-brain barrier. The interaction of hypertension with metabolic disorders exacerbates these effects. However, advancements in our understanding and new technologies reveal promising nanopharmacological approaches allowing targeted drug delivery to the brain, thereby improving treatment outcomes, enhancing adherence, and reducing side effects.
publishDate 2025
dc.date.none.fl_str_mv 2025-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/290988
Martín Giménez, Virna Margarita; García Menéndez, Sebastián Marcelo Manuel; Sanz, Raul Lelio; Schiavone, Máximo; Ferder, Leon Fernando; et al.; Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders; Baishideng Publishing Group; World Journal of Experimental Medicine; 15; 3; 9-2025; 1-9
2220-315X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/290988
identifier_str_mv Martín Giménez, Virna Margarita; García Menéndez, Sebastián Marcelo Manuel; Sanz, Raul Lelio; Schiavone, Máximo; Ferder, Leon Fernando; et al.; Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders; Baishideng Publishing Group; World Journal of Experimental Medicine; 15; 3; 9-2025; 1-9
2220-315X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/2220-315X/full/v15/i3/106743.htm
info:eu-repo/semantics/altIdentifier/doi/10.5493/wjem.v15.i3.106743
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Baishideng Publishing Group
publisher.none.fl_str_mv Baishideng Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1874774945228128256
score 13.24418

Publicaciones similares